Identification and Characterization of a Novel Integrin-Linked Kinase Inhibitor
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Integrin-linked kinase (ILK) represents a relevant target for cancer therapy in light of its role in promoting oncogenesis and tumor progression. Through the screening of an in-house focused compound library, we identified N-methyl-3-(1-(4-(piperazin-1-yl)phenyl)-5-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)-1H-pyrazol-3-yl)propanamide (22) as a novel ILK inhibitor (IC(50), 0.6 μM), which exhibited high in vitro potency against a panel of prostate and breast cancer cell lines (IC(50), 1-2.5 μM), while normal epithelial cells were unaffected. Compound 22 facilitated the dephosphorylation of Akt at Ser-473 and other ILK targets, including glycogen synthase kinase-3β and myosin light chain. Moreover, 22 suppressed the expression of the transcription/translation factor YB-1 and its targets HER2 and EGFR in PC-3 cells, which could be rescued by the stable expression of constitutively active ILK. Evidence indicates that 22 induced autophagy and apoptosis, both of which were integral to its antiproliferative activity. Together, this broad spectrum of mechanisms underlies the therapeutic potential of 22 in cancer treatment, which is manifested by its in vivo efficacy as a single oral agent in suppressing PC-3 xenograft tumor growth.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
García-Martínez, J. M., & Alessi, D. R. (2008) · Biochemical Journal · doi:10.1042/bj20081668 · Cited by 907
Su, J.-L., Chiou, J., Tang, C.-H., Zhao, M., Tsai, C.-H., Chen, P.-S., Chang, Y.-W., Chien, M.-H., Peng, C.-Y., Hsiao, M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.087122 · Cited by 121
Cited by
Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy
Jiang, Y., Zhang, H., Wang, J., Liu, Y., Luo, T., & Hua, H. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01252-0 · Cited by 491
Extracellular matrix stiffness: Mechanisms in tumor progression and therapeutic potential in cancer
Zhang, M., & Zhang, B. (2025) · Experimental Hematology & Oncology · doi:10.1186/s40164-025-00647-2 · Cited by 269
Klontzas, M. E., Reakasame, S., Silva, R., Morais, J. C. F., Vernardis, S., MacFarlane, R. J., Heliotis, M., Tsiridis, E., Panoskaltsis, N., Boccaccini, A. R., et al. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.02.017 · Cited by 77
Zoppi, N., Chiarelli, N., Binetti, S., Ritelli, M., & Colombi, M. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.01.005 · Cited by 49
Chou, C.-C., Chuang, H.-C., Salunke, S. B., Kulp, S. K., & Chen, C.-S. (2015) · Oncotarget · doi:10.18632/oncotarget.3186 · Cited by 50
Self-citationZoppi, N., Chiarelli, N., Ritelli, M., & Colombi, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19040982 · Cited by 37
“In this regard, ILK may act as kinase downstream the PI3K signaling pathway [150] and could be involved in the negative regulation, through the phosphorylation of a specific serine residue, of the glycogen synthase kinase 3β (GSK-3β) [151].”
BackgroundInfluential
Metadata
- Authors
- Lee, S.-L., Hsu, E.-C., Chou, C.-C., Chuang, H.-C., Bai, L.-Y., Kulp, S. K., & Chen, C.-S.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2011-08-24
- Volume
- 54
- Issue
- 18
- Pages
- 6364-6374
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2160159092
- Cited by
- 106
- References
- 2
- FWCI
- 2.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.